Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New perspectives on selective alpha 1 blockade.

R R Luther1

  • 1Pharmaceutical Products Division, Abbott Laboratories, IL 60064.

American Journal of Hypertension
|September 1, 1989
PubMed
Summary

Selective alpha 1 adrenergic receptor antagonists effectively lower blood pressure and improve cardiovascular risk factors. These agents offer a favorable safety profile, making them suitable for essential hypertension management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The management of severe chronic pain with a focus on new treatment modalities.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2000
Same author

Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.

Regional anesthesia and pain medicine·2000
Same author

Effects of an N-type calcium channel antagonist (SNX 111; Ziconotide) on calcium-45 accumulation following fluid-percussion injury.

Journal of neurotrauma·1999
Same author

Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects.

American journal of hypertension·1999
Same author

The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.

Critical care medicine·1999

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hypertension Management

Background:

  • Essential hypertension is characterized by increased peripheral vascular resistance.
  • Selective alpha 1 adrenergic receptor antagonists are a class of antihypertensive medications.
  • Prazosin and terazosin are examples of alpha 1 antagonists with established clinical use.

Purpose of the Study:

  • To evaluate the efficacy and safety of selective alpha 1 adrenergic receptor antagonists in managing essential hypertension.
  • To assess the impact of these agents on cardiovascular risk factors.
  • To determine the suitability of alpha 1 antagonists as first-line antihypertensive therapy.

Main Methods:

  • Review of clinical data and studies on selective alpha 1 adrenergic receptor antagonists.
  • Analysis of adverse effect profiles, including dizziness, headache, and syncope.
  • Assessment of the impact on cardiovascular risk factors such as lipid profiles and left ventricular hypertrophy.

Main Results:

  • Alpha 1 antagonists effectively reduce blood pressure by decreasing peripheral vascular resistance.
  • Common side effects like dizziness and headache are generally well-tolerated and rarely lead to treatment discontinuation.
  • These agents do not adversely affect cardiovascular risk factors and may improve lipid profiles, reducing total and LDL cholesterol.

Conclusions:

  • Selective alpha 1 adrenergic receptor antagonists demonstrate a beneficial impact on multiple cardiovascular risk factors.
  • Their favorable safety profile and positive effects on lipids support their consideration as first-line therapy for essential hypertension.
  • Optimizing cardiovascular risk management through antihypertensive choice is crucial for improving patient morbidity and mortality outcomes.

Related Experiment Videos